MARKET

PTCT

PTCT

PTC Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

45.46
-1.76
-3.73%
After Hours: 45.46 0 0.00% 16:00 09/21 EDT
OPEN
46.66
PREV CLOSE
47.22
HIGH
47.55
LOW
45.16
VOLUME
529.32K
TURNOVER
--
52 WEEK HIGH
59.89
52 WEEK LOW
30.79
MARKET CAP
3.08B
P/E (TTM)
-6.5834
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Hedge Funds Are Dipping Their Toes Back Into PTC Therapeutics, Inc. (PTCT)
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). We reversed our stance on March 25th after seeing unprecedented fiscal and monetary stimulus unleashed by the Fed and the Congress
Insider Monkey · 6d ago
Should You Take Comfort From Insider Transactions At PTC Therapeutics, Inc. (NASDAQ:PTCT)?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
Simply Wall St. · 09/14 20:20
PTC Therapeutics Launches PTC PINPOINT - A Genetic Testing Program for Individuals Suspected of Having Neurotransmitter Disorders
PTC Therapeutics, Inc. (NASDAQ: PTCT) today introduced a new program that provides genetic testing and counseling for people who may have a neurotransmitter disorder, such as aromatic L-amino acid decarboxylase (AADC) deficiency. The program, called PTC PINPOINT, will offer the testing at no charge to
PR Newswire · 09/09 13:00
PTC Therapeutics' 2020 STRIVE Awards for Duchenne Muscular Dystrophy Recognize Four Patient Advocacy Organizations
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the winners of its sixth annual STRIVE Awards grant program for Duchenne muscular dystrophy. This year's winning initiatives, spanning across four continents, include an online platform to improve peer-to-peer connections; a series of events designed
PR Newswire · 09/08 12:00
PTC Therapeutics to Present at the Cantor Virtual Global Healthcare Conference
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the Cantor Virtual Global Healthcare Conference on Thursday, September 17th at 9:20 a.m. ET.
PR Newswire · 09/03 12:00
Editas Medicine Review Plus Now - Better Choice Of PTC Therapeutics
In Late October last year we subjected Editas Medicine to an investment behavioral analysis because its developmental approach relies on genome editing.Then (before COVID-19) the analysis appeared quite promising of near-term capital gains under the discipline of TERMD portfolio management, in comparison to other biotech developers.The EDIT forecast of +20% gain was attained and pocketed in less than a month. Now, is reinvestment in EDIT as attractive again as similar biotech developer alternatives?With over 400 biotech-developer stocks available we once more use the behavior of investors – via their Yahoo Finance research-reading interests – in combing appropriate comparisons of alternatives.Enough change in institutional investment interest near-term has occurred to consider PTCT and XLRN more interesting and productive near-term capital gain alternatives instead.
Seekingalpha · 08/28 13:20
PTC Therapeutics Gets First Milestone Payment for SMA Drug
PTC Therapeutics (PTCT) gets first commercial milestone payment from Roche for first commercial sale of Evrysdi in the United States.
Zacks · 08/27 14:39
PTC reports first milestone payment from Roche for spinal muscular atrophy drug
Shares of PTC Therapeutics Inc. undefined were down 0.9% in trading on Wednesday after the company said it received its first milestone payment of $20...
MarketWatch · 08/26 14:44
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PTCT stock price target is 60.20 with a high estimate of 86.00 and a low estimate of 45.00.
EPS
Institutional Holdings
Institutions: 296
Institutional Holdings: 70.84M
% Owned: 104.63%
Shares Outstanding: 67.70M
TypeInstitutionsShares
Increased
87
9.49M
New
55
-597.64K
Decreased
56
4.15M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.77%
Pharmaceuticals & Medical Research
-2.28%
Key Executives
Chairman/Independent Director
Michael Schmertzler
Chief Executive Officer/Director
Stuart Peltz
Chief Financial Officer/Treasurer
Emily Hill
Chief Operating Officer
Marcio Souza
Executive Vice President
Mark Boulding
Senior Vice President - Finance/Chief Accounting Officer
Christine Utter
Other
Neil Almstead
Other
Matthew Klein
Other
Eric Pauwels
Independent Director
Allan Jacobson
Independent Director
Stephanie Okey
Independent Director
Emma Reeve
Independent Director
David Southwell
Independent Director
Glenn Steele
Independent Director
Dawn Svoronos
Independent Director
Jerome Zeldis
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More

Analyst Price Target

The average PTCT stock price target is 60.20 with a high estimate of 86.00 and a low estimate of 45.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About PTCT
PTC Therapeutics, Inc. is a science-driven global biopharmaceutical company. The Company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. The Company have a portfolio pipeline that includes commercial products as well as product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The Company have two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD). The Company have a pipeline of gene therapy product candidates for rare monogenic diseases that affect the central nervous system (CNS), including PTC-AADC for the treatment of Aromatic L-Amino Acid Decarboxylase (AADC) and CNSA-001 for phenylketonuria (PKU) diseases.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of PTC Therapeutics, Inc. stock information, including NASDAQ:PTCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTCT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PTCT stock methods without spending real money on the virtual paper trading platform.